Atopic Dermatitis Drugs Market

The global atopic dermatitis drugs market size is expected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rapid development of novel therapeutics and rising use of targeted therapies. Additionally, rising number of cases along with the high population under risk of infections presents a key aspect of the market expansion.

Get Free Sample Report

Atopic dermatitis (AD) is a type of eczema, which has impacted a large proportion of the population around the world. It can affect anyone at any time in their lifetime but mostly children or infants are mostly affected by this health condition. However, the disorder weakens its impact with age, and less number of cases are observed in old age people. The cause of the disease is unknown; however, the disease is predicted to result from genetic factors and environmental-related factors. Around 60% of patients with AD show indications in the early year and nearly 90% of patients display symptoms by the age of five, as per a global health report. The person with eczema develops symptoms such as dry skin, itching, and pain on the skin of ankles, upper chest, hands, feet, neck, eyelids, wrists, inside the bend of the elbows and knees, and for infants, the face and scalp are the target sites.

One in 10 people globally are likely to suffer from eczema during their life, with high frequency in early-stage of childhood, as per the National Eczema Association. The report also suggests that 31.6 million people from the U.S. are suffering from some form of eczema. Patients suffering from eczema need to be attentive towards allergies as allergies can aggravate the disease conditions. According to the report of the American College of Allergy, Asthma & Immunology children and infants are mostly affected by atopic dermatitis, and the allergy-related worsening of the disease is projected to be around 10% to 20% of those suffering from eczema.

The market report finds the Covid-19 pandemic demonstrated some negative impact on the market, due to shifting focus to the pandemic rapidly and leaving other healthcare burdens unattended globally. Various government initiatives to reduce the burden on the healthcare sector by postponing non-emergency services and nationwide lockdowns have caused to slow down the development of AD drugs. However, the world has witnessed a decline in COVID-19 cases in the second half of 2020 and relaxations on the restrictions, which present key opportunities for market expansion.

Market Trends, Drivers, Restraints, and Opportunities

• Initiatives taken by governments to provide more affordable and better treatment along with the existence of advantageous reimbursement policies are major factors driving the market growth.
• Rising approval of targeted therapy drugs such as Eucrisa and Dupixent is bolstering the market expansion.
• Introduction of new biologics, treatment methods, and development in the diagnostic kits for AD drug manufacturing are expected to boost the market revenue.
• Replacement of primary therapies with the availability of second-line as well as premium-priced drugs is a promising development that can propel the market.
• High cost of the drugs and therapy in the market is proving to be a major challenge for the market in the coming future.
• Vast scope of unserved and underdeveloped segments such as the pediatric population and rarer subtypes offers ample business opportunities for market expansion during the forecast period.

Scope of Atopic Dermatitis Drugs Market Report

The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Atopic Dermatitis Drugs Market Segment Insights

Based on drug class, the global atopic dermatitis drugs market is divided into PDE4 inhibitors, corticosteroids, calcineurin inhibitors, biologics, and others. The corticosteroids segment is expected to grow at a rapid pace, owing to the fact that corticosteroids is the first-line treatment for the disease. Calcineurin inhibitors has demonstrated the chances of developing carcinogenesis and nephrotoxicity. Toxic effects, non-specificity, and development of tolerance to this drug's class proved to be key hindrances in the growth of the segment and boost shifting to other targeted therapies.

The biologics segment is expected to constitute a large share of the market during the projected period as there is a high number of pipeline candidates for launch along with increasing acceptance of targeted therapy. If the severe patient has shown no response to first-line therapies, then the biologics drugs are used as the second or third-line of treatment.

Get Free Sample Report

On the basis of route of administration, the market is segmented into topical, injectable, and oral. The topical segment is projected to expand at a considerable CAGR during the forecast period, owing to the wide adoption of the topical type as it provides fast relief to patients. The topical medication is widely prescribed by the doctors along with moisturizers and emollients for more effective results.

The injectable segment is expected to exhibit a high CAGR during the forecast period as the rising development in a number of new more effective products. The oral segment is projected to hold a key market share, due to its rising popularity with time as the antihistamines, antibiotics, and anti-inflammatory agents are administrated through oral routes.

Get Free Sample Report

In terms of region, the global atopic dermatitis drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the projection period, due to the high awareness among the population, government initiatives, and high funding from government and non-government organizations. Additionally, the rise in research activities and developments along with a high number of approvals of therapy drugs is driving the regional market.

The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, owing to the noteworthy number of unmet needs of patients, the availability of effective treatment, and high spending on healthcare among a large number of population in the region.

Segments

• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

• Topical
• Injectable
• Oral

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Bausch Health Companies Inc. 
• Astellas Pharma US, Inc.
• Mylan
• Bayer AG
• Allergan
• LEO Pharma
• Pfizer, Inc.
• Regeneron Pharmaceutical, Inc.
• Anacor Pharmaceuticals, Inc.

Competitive Landscape

Key players competing in the global atopic dermatitis drugs market are Valeant Pharmaceuticals; Astellas Pharma US, Inc.; Mylan; Bayer AG; Allergan; LEO Pharma; Pfizer, Inc.; Regeneron Pharmaceutical, Inc.; and Anacor Pharmaceuticals, Inc.

Sanofi and Pfizer are set to top the competitive landscape by 2022, which is attributed to increase in acceptance of targeted therapies - Dupixent and Eucrisa - respectively. Both these drugs are projected to accomplish blockbuster drug position and is set to achieve highest revenue by 2022. Dupixent is undergoing investigation for treatment in pediatric patients. Various biologics such as fezakinumab, nemolizumab, tralokinumab, and lebrikizumab are in the pipeline by several major players in the market.